Pfizer Australia and BioNTech announce TGA approval for Omicron XBB.1.5-adapted monovalent COVID-19 vaccine

The FDA on Fri­day un­veiled new de­tails around a rare dis­ease pi­lot pro­gram that seeks to in­crease rapid, ad-hoc com­mu­ni­ca­tions be­tween six spon­sors work­ing on

Whether the investigational sickle cell disease therapy exagamglogene autotemcel (exa-cel) has adequately proven that it won’t produce off-target genetic changes was questioned by FDA reviewers